BLK vs MRSN · P/E 27, rev $24.22B vs rev $40.5M
BlackRock Inc (BLK) versus Mersana Therapeutics Inc (MRSN) — a side-by-side from cached financials, not a winner call.
BlackRock Inc (BLK) is a asset management company listed on NYSE. It is led by Laurence Douglas Fink.
Mersana Therapeutics Inc (MRSN) is a biotechnology company listed on NASDAQ.
Latest reported BLK revenue for 2025-12-31 was $24.22B. Net income was $5.55B. Revenue was up 89.3% from 2024-12-31 to 2025-12-31. BLK currently screens at market cap $172.19B and trailing P/E 26.6.
Latest reported MRSN revenue for 2024-12-31 was $40.5M. Net income was -$69.2M. Revenue was up 9.9% from 2023-12-31 to 2024-12-31. MRSN currently screens at market cap $145.4M.
BLK currently screens at market cap $172.19B and trailing P/E 26.6. MRSN currently screens at market cap $145.4M.
Not investment advice. Open the BLK and MRSN stock pages for the full models.
Not investment advice.